Oxurion
Linda Knott has extensive experience in executive support and office management within the pharmaceutical industry. Since July 2012, Linda has served as an Assistant to the US Corporate Team and the Executive Chairman at ThromboGenics. Prior to this role, Linda worked as a Legal Assistant Consultant at Dey Pharma L.P., where responsibilities included managing legal department requests and maintaining contract logs. Earlier in Linda's career, as an Executive Assistant and Office Manager at Wolters Kluwer Pharma Solutions, management of a small executive office was successfully executed, providing support to various top executives. Additionally, Linda worked as an Executive Assistant to the VP of Marketing at Reliant Pharmaceuticals from October 2006 to April 2008.
This person is not in any offices
Oxurion
Oxurion (Euronext Brussels: OXUR - formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.